Extrapyramidal side-effects of antipsychotics in a randomised trial. - Wikidata - wikimedia - TriplyDB

Extrapyramidal side-effects of antipsychotics in a randomised trial.

Extrapyramidal side-effects of antipsychotics in a randomised trial.

http://www.wikidata.org/entity/Q30492645

about

Second-generation antipsychotics and extrapyramidal adverse effects Anticholinergics versus placebo for neuroleptic-induced parkinsonism Anticholinergics (various) for neuroleptic-induced parkinsonism Quetiapine versus other atypical antipsychotics for schizophrenia Antipsychotic drug treatment for elderly people with late-onset schizophrenia Ziprasidone versus other atypical antipsychotics for schizophrenia Quetiapine in the treatment of psychosis in Parkinson's disease MicroRNA dysregulation in psychiatric disease Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.Tardive dyskinesia: therapeutic options for an increasingly common disorder.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements Convergent evidence for abnormal striatal synaptic plasticity in dystonia.The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.An Integrative Perspective on the Role of Dopamine in Schizophrenia Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study.Neuropsychiatry of aggression.Ziprasidone hydrocloride: what role in the management of schizophrenia?Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics.Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Pharmacogenetics of antipsychotic-induced side effects An update of safety of clinically used atypical antipsychotics.Review of the safety of second-generation antipsychotics: are they really "atypically" safe for youth and adults?Evidence review and clinical guidance for the use of ziprasidone in Canada.Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.The association between weight change and symptom reduction in the CATIE schizophrenia trial.Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.Drug-induced parkinsonism in the elderly: incidence, management and prevention.Perphenazine suspension: a new, old treatment, side effects and continuous use.Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

P2860

Q21284676-57C9F37E-FBE1-4D65-9BF2-5B87F24C36C5 Q24194301-D634A079-47B8-40DA-90FC-682EF8E6C1CD Q24194831-D5A2119D-0CC8-48DB-811A-BB62A3E87A51 Q24202427-FFD3BFFC-1A53-4925-8FDD-85142624A19E Q24203649-6BDE1443-815F-4F35-9DDA-6C330473209E Q24240260-A01975C2-F8A5-4DB1-B0BD-7E532BA3B995 Q24628941-9FE60CFC-8513-4EEF-8CBB-1FAC03D021EC Q24630375-F19B4F90-27E2-4C14-ADE0-040B3D4180E6 Q28384572-88922470-2437-4154-8CB4-7F405BB45370 Q28477329-A67358C5-38BF-4047-9916-B70083BE8B69 Q30478035-98DF1AD7-D58A-4E46-BB24-27A77BA2E69A Q30566749-8CF5D82B-F9A3-4B2F-9930-C6BD23E5F37A Q33566124-293AD8E3-E4D5-4ADC-B49D-8E8E4F12236B Q33756951-AD580EF9-A6EA-475C-9377-A9704D55FEE5 Q33770747-D17B330F-C722-4E92-B459-73F23F96961C Q33811763-F1306193-15DE-484D-8DAF-A4000CF7439B Q33839379-B4ADBE13-8510-4074-B55E-6DBAC305FC77 Q34048566-6CF914D0-F162-4337-BFFF-81771589A830 Q34155826-5B982836-8ACF-49D1-9176-F4F5F47524DE Q34357931-84AAD730-4881-4E93-8813-51D89EEE341E Q34388086-9AC3134D-6C1E-4BFD-BDC5-8B68C9CB8889 Q34447349-ADFED0E9-2BF7-45A1-B908-C4D96A9C836A Q34480263-7BE1885B-5764-4756-8C43-608D234295B9 Q34620095-5E36E5D2-ED15-407B-8F28-296E4D4CFA09 Q34628702-960D1CAA-EA6C-4DC9-A45F-05134B2FEF59 Q34640811-64D6C6D5-DF8D-4FEF-B527-1EF1A4DA724B Q35237129-BFF5194B-C964-428C-B7DC-543C46B9F5E6 Q36062184-D354282E-8E48-4596-9EB8-78D235B5384F Q36302856-423A5422-1C8B-4DF6-8919-9F7FA0E5891A Q36588607-631D329A-0AD8-42E7-8962-58C0CCDC7DF3 Q36654483-52E3C0EE-3F31-48E1-8711-772EFE87F521 Q37212106-D9FF18E4-6689-4E08-AD40-7522F281E61B Q37302639-6099600C-76EA-429E-B7B0-4A17BF23DA77 Q37489656-28B4888B-0BB3-463E-AF25-AD8911A90DC8 Q37492362-BAC891AF-02C6-4A34-919D-FAD13611C541 Q37725147-5418A45A-89C1-4292-B736-90198478DECE Q37900615-62B136FE-73DE-4E61-81F4-F9BB405D28A4 Q37976411-E2BF5250-8DDD-404B-83A5-8116CBF8510E Q37978232-CC49A5F2-C331-43BB-80AC-CB89BA3984CB Q38016230-6E0BC61B-99BF-4FEA-BB5F-3BF8D1DC59F3

P2860

Extrapyramidal side-effects of antipsychotics in a randomised trial.

http://www.wikidata.org/entity/Q30492645

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@ast

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@en

type

label

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@ast

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@en

prefLabel

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@ast

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@en

P1433

Q30492645-789356A7-2F15-4ABE-BDF0-BCBB3B38C922

P1476

Q30492645-06C64897-A4C4-4FD1-A57C-B08589825A21

P2093

Q30492645-1A526123-68A4-4337-B3BA-AC030C96D657

Q30492645-21956B9E-7AAD-4D84-BDAF-A42EEF6D9DF9

Q30492645-2CB4F668-79B6-412E-938B-638C7611BD29

Q30492645-35C626E7-5A59-4618-8E5C-355EBCC4F198

Q30492645-691AD82B-50D3-46EA-9265-82F315EF489D

Q30492645-6BB968A6-62A4-4F8D-B215-3DCCB27D8984

Q30492645-828AD46D-03BD-4BBB-8776-D1357676AE1F

Q30492645-98661604-D86A-4353-86A1-A2193401604F

Q30492645-A52C75EE-4CEE-4D17-9F16-0EF99743F32D

Q30492645-B7008BB6-0B8E-4207-9D72-B90AEEDCDEF1

P2860

Q30492645-024DCC50-0B60-481F-811F-DE0B06DCE7A5

Q30492645-09DF1245-884C-48F0-AEB8-22601E09A82A

Q30492645-0EE89FA5-BF57-46BC-B1FD-1AFA017EE427

Q30492645-1A32A04B-3108-4D99-94C0-6B6FD1D437E6

Q30492645-20D69CE0-C8FA-4866-B1D8-3635424DFE51

Q30492645-24D1ED9D-AABA-45F4-9A1A-6626DDA5E97B

Q30492645-2B967C7E-FCBE-483E-BC45-7582B549BD0F

Q30492645-2D97B7D6-CCAB-4027-9E08-8ACAC8F1CE27

Q30492645-39937009-F256-41F7-9F9D-BBAE69B015FB

Q30492645-41F27F18-413C-4FCA-99B6-42E5F05D871C

P304

Q30492645-4CC2957A-51B8-47ED-B9E9-502E9FA7717F

P31

Q30492645-0EA76FBB-56C5-474C-B9C4-FEF0B6BD3550

P356

Q30492645-AFD73945-7D1A-4C97-A1B0-CDB4D00C18C7

P407

Q30492645-1AA7A2EF-91C7-4A6F-A9B7-6EEA9B0D6C1A

P433

Q30492645-6BE8A546-6924-4D2A-B1C5-613975D0F440

P478

Q30492645-A7C135C9-D521-4B66-8399-940C04747983

P50

Q30492645-F980BDD6-BE5A-43BD-89A3-567F46789FB5

P577

Q30492645-17E98DD1-9BE4-498D-A9FA-F845EB58AA54

P698

Q30492645-E717E050-A577-4989-A75D-DDA3AF26C9D0

P932

Q30492645-5233850F-F29E-4583-8821-3ACD4FCD4390

P356

BJP.BP.108.050088

P1433

British Journal of Psychiatry

P1476

Extrapyramidal side-effects of antipsychotics in a randomised trial.

@en

P2093

Bruce L Saltz

http://www.w3.org/2001/XMLSchema#string

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators

http://www.w3.org/2001/XMLSchema#string

Del D Miller

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Lieberman

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Marvin S Swartz

http://www.w3.org/2001/XMLSchema#string

Miranda H Chakos

http://www.w3.org/2001/XMLSchema#string

Richard S E Keefe

http://www.w3.org/2001/XMLSchema#string

Silvana Riggio

http://www.w3.org/2001/XMLSchema#string

Sonia M Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

A rating scale for drug-induced akathisia

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.

Prevalence of spontaneous dyskinesia in schizophrenia.

Review of incidence studies of tardive dyskinesia associated with typical antipsychotics.

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

P304

279-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1192/BJP.BP.108.050088

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

193

http://www.w3.org/2001/XMLSchema#string

P50

Robert A. Rosenheck

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18827289

http://www.w3.org/2001/XMLSchema#string

P932

2801816

http://www.w3.org/2001/XMLSchema#string